Clinical Trials Logo

Psoriatic Arthritis clinical trials

View clinical trials related to Psoriatic Arthritis.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06402396 Active, not recruiting - Clinical trials for Rheumatoid Arthritis

Assessing Pain by the painDETECT Questionnaire (PDQ)

Start date: January 2013
Phase:
Study type: Observational [Patient Registry]

Prospective cohort study using drug survival rates to assess the predictive value of the PDQ when used to classify patients into a non-neuropathic pain phenotype group (score <13) or a neuropathic pain phenotype group (score ≥13)

NCT ID: NCT05862584 Active, not recruiting - Clinical trials for Rheumatoid Arthritis

Impact of Air Pollution on the Course of Inflammatory Rheumatism

Start date: May 26, 2023
Phase: N/A
Study type: Interventional

The objective of this study is to see if there is a link between air pollution and inflammatory rheumatism (rheumatoid arthritis and ankylosing spondylitis) To do this, the investigators are going to follow a cohort of about 200-400 patients for 6 months by means of a self-questionnaire, which the investigators ask the patient to fill in once a week on a fixed day, and opposite the corresponding week to put the letter corresponding to the question concerning the activity of your disease: 3 possible answers: A: no flare-up, B: short flare-up of 1 to 3 days, C: persistent flare-up of more than 3 days Then the investigators will collect the questionnaire at the end of these 6 months and at each visit to the consultation or day hospital (on average every 4 to 6 weeks), and they will look to see if any relapses have occurred. At the same time the investigators will calculate the disease activity score (DAS or BASDAI) to have an objective score. Then in parallel they will look at the level of exposure to air pollution according to the place of residence and work of each patient. The hypothesis is that air pollution has an influence on the activity of inflammatory rheumatism.

NCT ID: NCT05855967 Active, not recruiting - Psoriatic Arthritis Clinical Trials

A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in India

Start date: June 27, 2023
Phase: Phase 4
Study type: Interventional

The main purpose of this study is to investigate the safety and tolerability of ixekizumab in participants in India with moderate-to-severe plaque psoriasis (PsO) or active psoriatic arthritis (PsA)

NCT ID: NCT05623345 Active, not recruiting - Psoriatic Arthritis Clinical Trials

Psoriatic Arthritis Study of Izokibep

Start date: November 21, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

Izokibep is a potent and selective inhibitor of interleukin (IL)-17A that is being developed for treatment of psoriatic arthritis (PsA). This study will evaluate the efficacy of izokibep in subjects with PsA.

NCT ID: NCT05424926 Active, not recruiting - Clinical trials for Rheumatoid Arthritis

Sub-cutaneous Infliximab in Inflammatory Rheumatic Disease

SIC2
Start date: February 24, 2023
Phase:
Study type: Observational

TNFα inhibitors have revolutionized the management of patients suffering from inflammatory diseases in the field of rheumatology. Infliximab remains widely used in France, and infliximab biosimilars have been routinely used since 2015 in Cochin Hospital with an interchangeability strategy validated by two real life studies. REMSIMA® 120 mg is the first authorized subcutaneous (SC) form of infliximab to be administered at a fixed dose of 120 mg every 2 weeks. Scarce information is available regarding the safety and efficacy of proposing a switch from IV infliximab to SC REMSIMA® in the subsets of patients suffering from different rheumatic diseases in daily care. The primary objective of the SIC2 study will be determine the retention rate of Remsima SC at 6 months. The investigators will recruit adult patients with rheumatoid arthritis, spondyloarthritis, psoriatic arthritis.

NCT ID: NCT05413044 Active, not recruiting - Clinical trials for Rheumatoid Arthritis

A Post-marketing Study to Assess the Safety of Abatacept in Sweden Using the Swedish Rheumatology Quality Register (SRQ) Register

Start date: July 1, 2019
Phase:
Study type: Observational

The purpose of this study is to collect real-world data in order to estimate the frequency of overall malignancies, melanoma, basal cell carcinoma, and squamous cell carcinoma in participants with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) enrolled in the SRQ Register in Sweden.

NCT ID: NCT05329896 Active, not recruiting - Psoriatic Arthritis Clinical Trials

Ticopa Serum Analysis: an Analysis of Blood Samples From the TICOPA Study

Start date: April 1, 2022
Phase:
Study type: Observational

A range of different drugs are available to treat psoriatic arthritis (PsA) inflammation. However, clinicians are unable to predict who will respond well to a given drug, who will fail to respond and who will develop side effects. Responder/non-responder effects may also differ for the skin and joint domains of PsA. Patients currently undergo a trial and error phase of treatment, sometimes withstanding a period of nonresponse, and thus pain and discomfort, for a period of time. Treatment failures also waste resources and undermine patient confidence. There is a pressing need to identify predictors for response / non response and side effects, and this study will utilise novel bioinformatics approaches to address this need. The samples and clinical information collected from participants in the TICOPA (Effect of tight control of inflammation in early psoriatic arthritis) study (1) are a valuable resource. The investigators aim to use these existing serum samples to determine the potential of molecular markers to predict patients' response to treatment both with regard to effects and side effects. This analysis could potentially lead to the identification of serum and clinical parameters which when measured in a defined combination would be predictive of patients' response to treatment. 1 https://doi.org/10.1016/S0140-6736(15)00347-5

NCT ID: NCT05283096 Active, not recruiting - Clinical trials for Rheumatoid Arthritis

Survey About Diet in Chronic Inflammatory Rheumatic Diseases

Start date: February 10, 2022
Phase:
Study type: Observational

A French Survey on patients' practices, knowledge and beliefs about diet in chronic inflammatory rheumatic diseases (rheumatoid arthritis, psoriatic arthritis, spondylarthritis) Use of a questionnaire about what patients have heard concerning diet and rheumatism, what kind of diet they tried eventually and how it affected their health and disease

NCT ID: NCT05215561 Active, not recruiting - Psoriatic Arthritis Clinical Trials

Special Drug Use-results Survey to Evaluate Safety and Efficacy of Cosentyx in Pediatric Patients With PsV, PsA, or GPP

Start date: February 14, 2022
Phase:
Study type: Observational

This is a multicenter, centrally registered observational study without a control group. This observational study is a specified drug use-results survey conducted under GPSP to collect information on safety and efficacy during the observation period (52 weeks after the start of treatment with this drug) in pediatric patients with psoriasis vulgaris, psoriatic arthritis, or pustular psoriasis who received this drug.

NCT ID: NCT05155098 Active, not recruiting - Psoriatic Arthritis Clinical Trials

2 Years Prospective Study to Collect Real-life Data on the Retention, Quality of Life, Effectiveness and Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis

PROMPT
Start date: March 25, 2022
Phase:
Study type: Observational

This is an observational, prospective primary data collection study. The duration of observation is 2 years after study enrolment date. Disease and treatment history will be retrospectively reviewed from medical record at enrollment with no time limits for the key diagnosis of enrolment (plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthropathy).